[ET Net News Agency, 13 December 2019] Luye Pharma Group Ltd. (02186) said Ansofaxine
Hydrochloride Extended Release Tablets (LY03005), a new chemical drug for the treatment of
major depressive disorder has begun Phase I Clinical Study in Japan.
LY03005 is a central nervous system product candidate being developed within new
compounds platform. It is a serotonin-norepinephrine-dopamine triple reuptake inhibitor
(SNDRI) in extended release tablet form for the treatment of major depressive disorder.
(RC)